Additionally, EHop-016 sensitizes HER2 overexpressing trastuzumab sensitive and resistant breast cancer cells to trastuzumab [44, 91–93], and was recently shown to overcome therapy resistance by combined cancer therapy with Akt/mTOR inhibitors [94]. Here, ERBB2 is linked to breast cancer.